@article{ef48d188af8c495f92e3362cc3f184e1,
title = "Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial",
abstract = "Background no treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis.",
author = "Fred Lublin and Miller, {David H.} and Freedman, {Mark S.} and Cree, {Bruce A. C.} and Wolinsky, {Jerry S.} and Howard Weiner and Catherine Lubetzki and Hans-Peter Hartung and Xavier Montalban and Uitdehaag, {Bernard M. J.} and Martin Merschhemke and Bingbing Li and Norman Putzki and Liu, {Fonda C.} and Haering, {Dieter A.} and {INFORMS study investigators} and Raymond Hupperts and Ludwig Kappos",
year = "2016",
month = mar,
day = "12",
doi = "10.1016/S0140-6736(15)01314-8",
language = "English",
volume = "387",
pages = "1075--1084",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Science",
number = "10023",
}